[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
June 9, 2015

Varenicline for Smoking Reduction Prior to Cessation

Author Affiliations
  • 1Veterans Affairs Medical Center, White River Junction, Vermont
JAMA. 2015;313(22):2285. doi:10.1001/jama.2015.4978

To the Editor In a recent study,1 the partial nicotinic receptor agonist varenicline offered a viable cessation aid for smokers unwilling or unable to quit immediately but who were amenable to cigarette reduction prior to delayed attempts at full smoking cessation. Although the data from this randomized, double-blind, placebo-controlled multicenter study suggested benefit, marked heterogeneity in the study population was observed that warrants closer scrutiny to potentially identify specific subsets of patients who are the most or the least likely to benefit from such interventions.